Envestnet Asset Management
NAVB

Envestnet Asset Management’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Envestnet Asset Management’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-221
Closed -$12K – 2599
2013
Q3 		$12K Sell
221
-17
-7% -$991 ﹤0.01% 1655
2013
Q2 		$13K Buy
+238
New +$11.9K ﹤0.01% 1584

Other funds holding NAVB

PM
Platinum Management New York $16.4M AUM 30.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Envestnet Asset Management's NAVB Position: Q4 2013 in Review

Envestnet Asset Management sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2013, closing a stake of 221 shares — an estimated $12K sold.

Envestnet Asset Management first reported a position in NAVB in Q2 2013 and held it in 2 quarters. The position peaked at $13K in Q2 2013. 87 funds tracked by Wall St. Rank hold NAVB as of Q4 2013.

  • Envestnet Asset Management reported no remaining Navidea Biopharmaceuticals Inc. position as of Q4 2013 after selling out during the quarter.
  • Envestnet Asset Management sold 221 Navidea Biopharmaceuticals Inc. shares in Q4 2013, an estimated $12K.
  • Envestnet Asset Management first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 2 quarters.
  • Envestnet Asset Management's Navidea Biopharmaceuticals Inc. position peaked at $13K in Q2 2013.
  • 87 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2013.

Based on Envestnet Asset Management's 13F filing for Q4 2013, filed 12 Feb 2014.